Healthcare, Pharma & Life Sciences

PDS Health Delivers $22.8M in Free Dental Care to 5,863 Patients

Image
PDS Health Delivers $22.8M in Free Dental Care to 5,863 Patients

Henderson, Nev. – September 20, 2026 -- PDS Health provided $22.8 million in donated dental services to 5,863 patients nationwide during its 16th annual Smile Generation Serve Day, held throughout August.

More than 14,000 team members logged 83,549 volunteer hours in one month

The integrated healthcare support organization mobilized over 14,000 staff members across its network of affiliated practices to deliver free treatment to individuals facing barriers to dental care. Since the initiative launched in 2011, cumulative donated care has reached more than $117 million.

Octagos Named Only Cardiac Monitoring Firm on TIME HealthTech List

Image
Octagos Named Only Cardiac Monitoring Firm on TIME HealthTech List

Houston – September 20, 2026 -- Octagos has been named to TIME and Statista's World's Top HealthTech Companies of 2026 list, marking the only cardiac implantable electronic device (CIED) monitoring company recognized in either the inaugural 2025 ranking or the 2026 edition.

TIME and Statista rank Octagos among 82 AI and Data Analytics firms out of 500 global honorees

The evaluation weighted financial performance at 50%, reputation at 30%, and online engagement at 20%. Octagos received a "Very High" performance rating within the AI and Data Analytics category, one of six categories spanning the 500-company list.

CND Life Sciences Opens Scottsdale Innovation Lab for Neurodiagnostics R&D

Image
CND Life Sciences Opens Scottsdale Innovation Lab for Neurodiagnostics R&D

Scottsdale, Ariz. – September 20, 2026 -- CND Life Sciences, Inc. has opened a new Innovation Laboratory in Scottsdale, Arizona, expanding its research and product-development capacity for neurodegenerative disease diagnostics. The facility was inaugurated with a ribbon-cutting ceremony attended by employees, community members, and key stakeholders, and operations are set to begin next week.

New facility separates R&D from clinical testing operations

The Innovation Laboratory operates independently from CND's existing CLIA-certified, CAP-accredited, and CLEP-permitted clinical laboratory, which processes the company's Syn-One Test. The new space is dedicated to assay development, biomarker research, technology evaluation, and translational research programs, allowing the company to pursue early-stage science without disrupting clinical throughput.

Virbac H1 2026 Revenue Rises 7.4%, Confirms Upper-End Guidance

Image
Virbac H1 2026 Revenue Rises 7.4%, Confirms Upper-End Guidance

Paris – September 20, 2026 -- Virbac posted first-half 2026 revenue growth of 7.4% at constant exchange rates and currencies (CERS), lifting its adjusted EBIT margin to 18.8%, up 0.5 percentage points from H1 2025.

Companion animal segment leads growth at 10.0%, farm animal follows at 6.7%

The animal health group's Supercharge platforms, excluding Thyronorm, expanded around 12% at CERS, becoming a key driver of top-line performance. Growth split into a volume/mix effect of approximately 5.4% and a price increase of roughly 2%.

Net income climbs 5.9% to €87.1 million

The margin gain stemmed from a favorable gross margin mix, partially offset by higher operating expenses tied to H1/H2 phasing effects.

PNH Drug Market to Reach $1.5B in 2025, Grow at 7.1% CAGR

Image
PNH Drug Market to Reach $1.5B in 2025, Grow at 7.1% CAGR

Las Vegas – September 20, 2026 -- The paroxysmal nocturnal hemoglobinuria (PNH) market across the seven major markets was valued at approximately $1.5 billion in 2025 and is projected to grow at a compound annual growth rate of 7.1% through 2036, according to DelveInsight.

Regeneron's pozelimab-cemdisiran combination leads next wave of PNH therapies

Pozelimab, a fully human anti-C5 monoclonal antibody developed on Regeneron's VelocImmune platform, is expected to generate the highest revenue among emerging PNH therapies in the seven major markets. The drug is being tested in combination with Alnylam's siRNA therapy cemdisiran; Regeneron has said Phase III results in PNH are anticipated in the fourth quarter of 2026 or the first quarter of 2027.

Eterna Regeneratives Raises Seed Funding for Keratin Enamel Repair Tech

Image
Eterna Regeneratives Raises Seed Funding for Keratin Enamel Repair Tech

London – September 20, 2026 -- UK biotech spin-out Eterna Regeneratives has closed a seed funding round led by Hoxton Ventures and The Venture Collective to commercialize a keratin-based material that regrows tooth enamel, targeting the $43 billion global oral care market.

King's College London spin-out moves from lab to commercial pipeline

Co-founded in 2024 by Khaled Eissa and Dr Sherif Elsharkawy, Eterna emerged from research led by Elsharkawy and PhD student Dr Sara Gamea that drew coverage from the BBC, Washington Post and Newsweek after demonstrating keratin's capacity to regrow damaged enamel. The seed round funds the shift from proof-of-concept research to real-world product development, according to Elsharkawy, the company's Chief Scientific Officer.

Ikonopedia Rolls Out BI-RADS v2025 Update to Breast Imaging Platform

Image
Ikonopedia Rolls Out BI-RADS v2025 Update to Breast Imaging Platform

Dallas – September 20, 2026 -- Ikonopedia deployed version 2026.08.0 of its breast imaging reporting platform on the evening of September 15, aligning the software with the American College of Radiology's newly released BI-RADS v2025 (6th Edition) manual.

Terminology overhaul removes ambiguous mammography and MRI terms

The update strips outdated language from structured reporting workflows across mammography, breast ultrasound, breast MRI, and pathology. Terms such as "developing asymmetry" in mammography and "focus" in breast MRI have been eliminated to match the revised ACR standard, reducing inconsistency in radiologist reporting.

DarioHealth Signs New Jersey Health Plan Covering 1.5M Lives via Amwell

Image
DarioHealth Signs New Jersey Health Plan Covering 1.5M Lives via Amwell

New York – September 20, 2026 -- DarioHealth Corp. (NASDAQ: DRIO) has secured a new contract with one of New Jersey's largest health plans, covering approximately 1.5 million lives, through its channel partnership with Amwell. The program covering Dario's cardiometabolic suite and provider-backed care is expected to launch and begin generating revenue in the first quarter of 2027.

Amwell channel delivers third major state health plan in 12 months

The New Jersey deal follows previously secured contracts with major health insurers in Arizona and Florida, marking the third large state health plan Dario has signed through Amwell within the past year. The customer operates as an administrative services only (ASO) health plan, giving Dario access to a broad population of self-funded employer groups eligible to deploy its cardiometabolic solutions.

Dualitas Signs Up to $1B Roche Deal for Bispecific Antibody Discovery

Image
Dualitas Signs Up to $1B Roche Deal for Bispecific Antibody Discovery

South San Francisco, Calif. – September 20, 2026 -- Dualitas Therapeutics has secured a research collaboration and license agreement with Roche worth up to $1 billion, including a $36.5 million upfront payment, to develop bispecific antibody therapeutics for immunology and inflammation diseases.

Dualitas will screen over 300,000 bispecific antibody combinations for Roche

Under the agreement, Dualitas will use its proprietary DualScreen Bispecific Discovery Engine to functionally screen more than 300,000 novel bispecific combinations, in what the company describes as one of the largest-scale bispecific discovery efforts undertaken. Roche will take over all subsequent preclinical development, regulatory, manufacturing and commercial activities for candidates that emerge from the collaboration.

Canary Speech Named to TIME's Top HealthTech Companies 2026 List

Image
Canary Speech Named to TIME's Top HealthTech Companies 2026 List

Provo, Utah – September 20, 2026 -- Canary Speech has been named to TIME and Statista's World's Top HealthTech Companies 2026 ranking, marking the second consecutive year the vocal biomarker technology firm has received the distinction.

TIME and Statista select 500 companies from thousands of HealthTech firms reviewed globally

The ranking evaluated companies across three primary data sources: Financial Performance Metrics, Reputation Analysis, and Online Engagement. The list was announced on September 20, 2026, and published on Time.com.